The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Treatment options in patients with rheumatoid arthritis failing initial TNF inhibitor therapy: a critical review
Open accessAbstract
Conventional disease-modifying antirheumatic drugs such as methotrexate are the mainstay of treatment for rheumatoid arthritis. More recently, biologic agents such as etanercept, infliximab and adalimumab, which act by inhibiting tumour necrosis factor (TNF), have become available. TNF inhibitors have proved to be very effective in patients not responding to conventional disease-modifying antirheumatic drugs. However, about 20% to 40% of patients treated with a TNF inhibitor fail to achieve a 20% improvement in American College of Rheumatology criteria, and more lose response over time (secondary failure or acquired therapeutic resistance) or experience adverse events following treatment with a TNF inhibitor. In this group of patients, therapeutic options were limited until recently and an established treatment approach was to switch from one TNF inhibitor to another. In recent years, therapeutic options in these patients have increased with the introduction of biologic agents with novel mechanisms of action, such as rituximab and abatacept. This review outlines the current evidence in support of the available treatment strategies in patients with an inadequate response or intolerance to an initial TNF inhibitor.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Infliximab and Methotrexate in the Treatment of Rheumatoid Arthritis
Lipsky, P. E., van der Heijde, D. M. F. M., St. Clair, E. W., Furst, D. E., Breedveld, F. C., Kalden, J. R., Smolen, J. S., Weisman, M., Emery, P., Feldmann, M., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011303432202 · Cited by 2,996
Bongartz, T., Sutton, A. J., Sweeting, M. J., Buchan, I., Matteson, E. L., & Montori, V. (2006) · JAMA · doi:10.1001/jama.295.19.2275 · Cited by 2,468
Maini, R., St Clair, E. W., Breedveld, F., Furst, D., Kalden, J., Weisman, M., Smolen, J., Emery, P., Harriman, G., Feldmann, M., et al. (1999) · The Lancet · doi:10.1016/s0140-6736(99)05246-0 · Cited by 2,345
Weinblatt, M. E., Kremer, J. M., Bankhurst, A. D., Bulpitt, K. J., Fleischmann, R. M., Fox, R. I., Jackson, C. G., Lange, M., & Burge, D. J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199901283400401 · Cited by 2,085
Breedveld, F. C., Weisman, M. H., Kavanaugh, A. F., Cohen, S. B., Pavelka, K., Vollenhoven, R. V., Sharp, J., Perez, J. L., & Spencer‐Green, G. T. (2006) · Arthritis & Rheumatism · doi:10.1002/art.21519 · Cited by 1,785
Weinblatt, M. E., Keystone, E. C., Furst, D. E., Moreland, L. W., Weisman, M. H., Birbara, C. A., Teoh, L. A., Fischkoff, S. A., & Chartash, E. K. (2003) · Arthritis & Rheumatism · doi:10.1002/art.10697 · Cited by 1,757
Klareskog, L., van der Heijde, D., de Jager, J. P., Gough, A., Kalden, J., Malaise, M., Mola, E. M., Pavelka, K., Sany, J., Settas, L., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)15640-7 · Cited by 1,751
A Comparison of Etanercept and Methotrexate in Patients with Early Rheumatoid Arthritis
Bathon, J. M., Martin, R. W., Fleischmann, R. M., Tesser, J. R., Schiff, M. H., Keystone, E. C., Genovese, M. C., Wasko, M. C., Moreland, L. W., Weaver, A. L., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011303432201 · Cited by 1,730
Cohen, S. B., Emery, P., Greenwald, M. W., Dougados, M., Furie, R. A., Genovese, M. C., Keystone, E. C., Loveless, J. E., Burmester, G., Cravets, M. W., et al. (2006) · Arthritis & Rheumatism · doi:10.1002/art.22025 · Cited by 1,638
Tumor necrosis factor antagonist mechanisms of action: A comprehensive review
Tracey, D., Klareskog, L., Sasso, E. H., Salfeld, J. G., & Tak, P. P. (2008) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2007.10.001 · Cited by 1,628
Lee, D. M., & Weinblatt, M. E. (2001) · The Lancet · doi:10.1016/s0140-6736(01)06075-5 · Cited by 1,247
Abatacept for Rheumatoid Arthritis Refractory to Tumor Necrosis Factor α Inhibition
Genovese, M. C., Becker, J.-C., Schiff, M., Luggen, M., Sherrer, Y., Kremer, J., Birbara, C., Box, J., Natarajan, K., Nuamah, I., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050524 · Cited by 1,241
Emery, P., Keystone, E., Tony, H. P., Cantagrel, A., van Vollenhoven, R., Sanchez, A., Alecock, E., Lee, J., & Kremer, J. (2008) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2008.092932 · Cited by 1,104
Etanercept plus Standard Therapy for Wegener's Granulomatosis
(2005) · New England Journal of Medicine · doi:10.1056/nejmoa041884 · Cited by 834
Treatment of Active Rheumatoid Arthritis With Leflunomide Compared With Placebo and Methotrexate
Strand, V. (1999) · Archives of Internal Medicine · doi:10.1001/archinte.159.21.2542 · Cited by 754
Kremer, J. M., Genant, H. K., Moreland, L. W., Russell, A. S., Emery, P., Abud-Mendoza, C., Szechinski, J., Li, T., Ge, Z., Becker, J.-C., et al. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-144-12-200606200-00003 · Cited by 715
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010
Furst, D. E., Keystone, E. C., Braun, J., Breedveld, F. C., Burmester, G. R., De Benedetti, F., Dörner, T., Emery, P., Fleischmann, R., Gibofsky, A., et al. (2011) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.146852 · Cited by 687
Infections in patients with rheumatoid arthritis treated with biologic agents
Listing, J., Strangfeld, A., Kary, S., Rau, R., von Hinueber, U., Stoyanova‐Scholz, M., Gromnica‐Ihle, E., Antoni, C., Herzer, P., Kekow, J., et al. (2005) · Arthritis & Rheumatism · doi:10.1002/art.21386 · Cited by 681
Wolfe, F., & Michaud, K. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20311 · Cited by 644
Wolfe, F., & Michaud, K. (2007) · Arthritis & Rheumatism · doi:10.1002/art.22864 · Cited by 534
Survival in rheumatoid arthritis: A population‐based analysis of trends over 40 years
Gabriel, S. E., Crowson, C. S., Kremers, H. M., Doran, M. F., Turesson, C., O'Fallon, W. M., & Matteson, E. L. (2003) · Arthritis & Rheumatism · doi:10.1002/art.10705 · Cited by 516
Mackey, A. C., Green, L., Liang, L., Dinndorf, P., & Avigan, M. (2007) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/mpg.0b013e31802f6424 · Cited by 506
Smolen, J. S., Han, C., Bala, M., Maini, R. N., Kalden, J. R., van der Heijde, D., Breedveld, F. C., Furst, D. E., Lipsky, P. E., & ATTRACT Study Group (2005) · Arthritis & Rheumatism · doi:10.1002/art.20982 · Cited by 462
Smolen, J. S., Van Der Heijde, D. M. F. M., St.Clair, E. W., Emery, P., Bathon, J. M., Keystone, E., Maini, R. N., Kalden, J. R., Schiff, M., Baker, D., et al. (2006) · Arthritis & Rheumatism · doi:10.1002/art.21678 · Cited by 434
Takeuchi, T., Tatsuki, Y., Nogami, Y., Ishiguro, N., Tanaka, Y., Yamanaka, H., Kamatani, N., Harigai, M., Ryu, J., Inoue, K., et al. (2008) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2007.072967 · Cited by 402
Hyrich, K. L., Lunt, M., Watson, K. D., Symmons, D. P. M., Silman, A. J., & British Society for Rheumatology Biologics Register (2007) · Arthritis & Rheumatism · doi:10.1002/art.22331 · Cited by 401
Radstake, T. R. D. J., Svenson, M., Eijsbouts, A. M., van den Hoogen, F. H. J., Enevold, C., van Riel, P. L. C. M., & Bendtzen, K. (2009) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2008.092833 · Cited by 377
Askling, J., Fored, C. M., Brandt, L., Baecklund, E., Bertilsson, L., Feltelius, N., Cöster, L., Geborek, P., Jacobsson, L. T., Lindblad, S., et al. (2007) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2006.062760 · Cited by 334
Gomez-Reino, J. J., Carmona, L., & the BIOBADASER Group (2006) · Arthritis Research & Therapy · doi:10.1186/ar1881 · Cited by 289
Measuring function in rheumatoid arthritis: Identifying reversible and irreversible components
Aletaha, D., Smolen, J., & Ward, M. M. (2006) · Arthritis & Rheumatism · doi:10.1002/art.22052 · Cited by 276
Keystone, E., Emery, P., Peterfy, C. G., Tak, P. P., Cohen, S., Genovese, M. C., Dougados, M., Burmester, G. R., Greenwald, M., Kvien, T. K., et al. (2009) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2007.085787 · Cited by 227
The Benefit/Risk Profile of TNF-Blocking Agents: Findings of a Consensus Panel
Hochberg, M. C., Lebwohl, M. G., Plevy, S. E., Hobbs, K. F., & Yocum, D. E. (2005) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2004.11.006 · Cited by 203
Bombardieri, S., Ruiz, A. A., Fardellone, P., Geusens, P., McKenna, F., Unnebrink, K., Oezer, U., Kary, S., Kupper, H., Burmester, G. R., et al. (2007) · Rheumatology · doi:10.1093/rheumatology/kem091 · Cited by 179
Finckh, A., Simard, J. F., Gabay, C., & Guerne, P.-A. (2006) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2005.045062 · Cited by 176
Self-citationFinckh, A., Ciurea, A., Brulhart, L., Möller, B., Walker, U. A., Courvoisier, D., Kyburz, D., Dudler, J., & Gabay, C. (2010) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2008.105064 · Cited by 169
Self-citationUpdated consensus statement on biological agents for the treatment of rheumatic diseases, 2007
Furst, D. E., Breedveld, F. C., Kalden, J. R., Smolen, J. S., Burmester, G. R., Sieper, J., Emery, P., Keystone, E., Schiff, M., Mease, P. J., et al. (2007) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2007.081430 · Cited by 153
Braun, J., Baraliakos, X., Listing, J., Fritz, C., Alten, R., Burmester, G. R., Krause, A., Schewe, S., Schneider, M., Sörensen, H., et al. (2007) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2007.075879 · Cited by 144
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2011
Fürst, D. E., Keystone, E. C., Braun, J. M., Fc, B., Burmester, G. R., Benedetti, F. D., Dörner, T., Emery, P., Fleischmann, R., Gibofsky, A., et al. (2012) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2011-201036 · Cited by 122
Keystone, E., Burmester, G., Furie, R., Loveless, J., Emery, P., Kremer, J., Tak, P., Broder, M., Yu, E., Cravets, M., et al. (2008) · Arthritis & Rheumatism · doi:10.1002/art.23715 · Cited by 111
Long-term infliximab treatment in rheumatoid arthritis: subsequent outcome of initial responders
Buch, M. H., Bingham, S. J., Bryer, D. J., & Emery, P. (2007) · Lara D. Veeken · doi:10.1093/rheumatology/kem075 · Cited by 100
Mikuls, T. R., Saag, K. G., Criswell, L. A., Merlino, L. A., Kaslow, R. A., Shelton, B. J., & Cerhan, J. R. (2002) · Annals of the Rheumatic Diseases · doi:10.1136/ard.61.11.994 · Cited by 97
Kimpel, D. L. (2007) · Yearbook of Medicine · doi:10.1016/s0084-3873(08)70005-1 · Cited by 86
Hyrich, K. L., Lunt, M., Dixon, W. G., Watson, K. D., Symmons, D. P. M., & Register, O. B. O. T. B. B. (2008) · Rheumatology · doi:10.1093/rheumatology/ken127 · Cited by 75
Pincus, T., Kavanaugh, A., & Sokka, T. (2004) · PubMed · Cited by 32
Cited by
Emerging Role of Endosomal Toll-Like Receptors in Rheumatoid Arthritis
Thwaites, R., Chamberlain, G., & Sacre, S. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00001 · Cited by 748
Genovese, M. C., Fleischmann, R., Combe, B., Hall, S., Rubbert-Roth, A., Zhang, Y., Zhou, Y., Mohamed, M.-E. F., Meerwein, S., & Pangan, A. L. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31116-4 · Cited by 422
Self-citationCyclometalated iridium(III) luminescent complexes in therapy and phototherapy
Zamora, A., Vigueras, G., Rodríguez, V., Santana, M. D., & Ruiz, J. (2018) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2018.01.010 · Cited by 345
Assessing Response and Loss of Response to Biological Therapies in IBD
Yanai, H., & Hanauer, S. B. (2011) · American Journal of Gastroenterology · doi:10.1038/ajg.2011.103 · Cited by 326
Malottki, K., Barton, P., Tsourapas, A., Uthman, A., Liu, Z., Routh, K., Connock, M., Jobanputra, P., Moore, D., Fry-Smith, A., et al. (2011) · Health Technology Assessment · doi:10.3310/hta15140 · Cited by 287
Metadata
- Authors
- Rubbert-Roth, A., & Finckh, A.
- Venue
- Arthritis Research & Therapy
- Published
- 2009
- Volume
- 11
- Issue
- Suppl 1
- Pages
- S1
- ISSN
- 1478-6354 (ISSN-L)
- OpenAlex
- W2096839909
- Cited by
- 266
- References
- 44
- Type
- conference abstract
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.